fluorouracil has been researched along with Cancer of Muscle in 7 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed effectiveness, safety, and tolerability of paclitaxel or fluorouracil when added to radiation plus cisplatin followed by adjuvant chemotherapy in a programme of selected bladder preservation for patients with muscle invasive bladder cancer." | 9.17 | Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase ( Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL, 2013) |
| "We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 7.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
| "We assessed effectiveness, safety, and tolerability of paclitaxel or fluorouracil when added to radiation plus cisplatin followed by adjuvant chemotherapy in a programme of selected bladder preservation for patients with muscle invasive bladder cancer." | 5.17 | Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase ( Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL, 2013) |
| "We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 3.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
| "Sixty-one patients with muscle-invasive bladder cancer who underwent CCRT between January 1996 and March 2011 were eligible for evaluation." | 1.39 | Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy. ( Chuang, CK; Hong, JH; Liaw, CC; Lin, YC; Pang, ST; Wu, CE, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto, Y | 1 |
| Nakashima, Y | 1 |
| Sasaki, S | 1 |
| Jogo, T | 1 |
| Hirose, K | 1 |
| Edahiro, K | 1 |
| Korehisa, S | 1 |
| Taniguchi, D | 1 |
| Kudou, K | 1 |
| Nakaji, YU | 1 |
| Nakanishi, R | 1 |
| Ando, K | 1 |
| Saeki, H | 1 |
| Oki, E | 1 |
| Fujiwara, M | 1 |
| Oda, Y | 1 |
| Maehara, Y | 1 |
| Wu, CE | 1 |
| Lin, YC | 1 |
| Hong, JH | 1 |
| Chuang, CK | 1 |
| Pang, ST | 1 |
| Liaw, CC | 1 |
| Mitin, T | 1 |
| Hunt, D | 1 |
| Shipley, WU | 1 |
| Kaufman, DS | 1 |
| Uzzo, R | 1 |
| Wu, CL | 1 |
| Buyyounouski, MK | 1 |
| Sandler, H | 1 |
| Zietman, AL | 1 |
| Noda, T | 1 |
| Nagano, H | 1 |
| Marubashi, S | 1 |
| Kobayashi, S | 1 |
| Takeda, Y | 1 |
| Murakami, M | 1 |
| Tomimaru, Y | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Nakayama, M | 1 |
| Shima, T | 1 |
| Wakasa, K | 1 |
| Monden, M | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Yoshimasu, T | 1 |
| Oura, S | 1 |
| Hirai, I | 1 |
| Kokawa, Y | 1 |
| Nishida, M | 1 |
| Sasaki, R | 1 |
| Kawago, M | 1 |
| Yuzaki, M | 1 |
| Tanino, H | 1 |
| Sakurai, T | 1 |
| Okamura, Y | 1 |
| Higano, CS | 1 |
| Tangen, CM | 1 |
| Sakr, WA | 1 |
| Faulkner, J | 1 |
| Rivkin, SE | 1 |
| Meyers, FJ | 1 |
| Hussain, M | 1 |
| Baker, LH | 1 |
| Russell, KJ | 1 |
| Crawford, ED | 1 |
| Heidemann, J | 1 |
| Gockel, HR | 1 |
| Winde, G | 1 |
| Herbst, H | 1 |
| Domschke, W | 1 |
| Lügering, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabi[NCT00055601] | Phase 2 | 97 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bladder-intact survival was measured from the date of randomization to occurrence of cystectomy or death. Five-year rates were estimated using the Kaplan-Meier method. (NCT00055601)
Timeframe: From the date of randomization to five years.
| Intervention | percentage of participants (Number) |
|---|---|
| Pelvic RT + Paclitaxel + Cisplatin | 67 |
| Pelvic RT + Fluorouracil + Cisplatin | 71 |
Complete response requires the absence of any tumor in the tumor-site biopsy specimen or elsewhere and a bimanual exam that does not indicate the presence of a tumor mass. (NCT00055601)
Timeframe: From randomization to eight weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pelvic RT + Paclitaxel + Cisplatin | 72 |
| Pelvic RT + Fluorouracil + Cisplatin | 62 |
Radiation therapy and chemotherapy per protocol or within acceptable variation guidelines based on central review. The study was designed for a two-sided binomial test with 87% power and a significance level of 0.05 with a null hypothesis of a 70% completion rate against the alternative 90% completion rate. For each arm, more than 34 out of 43 evaluable patients completing the treatment, would indicate to reject the null hypothesis for a better treatment completion rate. Fewer than 24 out 43 evaluable patients completing the treatment would indicate to reject the null hypothesis for a worse treatment completion rate. Otherwise, the conclusion would be that there is not enough evidence to reject the null hypothesis of a 70% completion rate in either direction. (NCT00055601)
Timeframe: From randomization to 11 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pelvic RT + Paclitaxel + Cisplatin | 67 |
| Pelvic RT + Fluorouracil + Cisplatin | 53 |
1 review available for fluorouracil and Cancer of Muscle
| Article | Year |
|---|---|
Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous | 2017 |
1 trial available for fluorouracil and Cancer of Muscle
| Article | Year |
|---|---|
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2013 |
5 other studies available for fluorouracil and Cancer of Muscle
| Article | Year |
|---|---|
Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemorad | 2013 |
[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chola | 2008 |
[Histoculture drug response assay for solitary fibrous tumor--a case report].
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Diaphragm; Docetaxel; Doxorubicin; Drug Screening A | 2004 |
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2008 |
Signet-ring cell carcinoma of unknown primary location. Metastatic to lower back musculature - remission following FU/FA chemotherapy.
Topics: Abdominal Neoplasms; Aged; Back; Biopsy, Needle; Carcinoma, Signet Ring Cell; Diagnosis, Differentia | 2002 |